| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/03/2001 | CA2388599A1 Drosophila g protein coupled receptors, nucleic acids, and methods related to the same |
| 05/03/2001 | CA2388483A1 Process for producing optically active naphthalene derivative and optical resolver therefor |
| 05/03/2001 | CA2388479A1 Preventives or remedies for arrhythmia |
| 05/03/2001 | CA2388337A1 Method of inducing and/or enhancing an immune response to tumor antigens |
| 05/03/2001 | CA2388313A1 Silicon compounds derived from ascorbic acid |
| 05/03/2001 | CA2388298A1 The use of csf-1 inhibitors |
| 05/03/2001 | CA2388203A1 Microbe, microbial exopolysaccharide, and uses thereof |
| 05/03/2001 | CA2388130A1 Molecularly imprinted polymers produced by template polymerisation |
| 05/03/2001 | CA2388123A1 Oral dosage form comprising a salt of morphine or a morphine derivative |
| 05/03/2001 | CA2388121A1 Phthalazinone derivatives as pde 4 inhibitors |
| 05/03/2001 | CA2388119A1 Tetrahydrothiopy ranphthalazinone derivatives as pde4 inhibitors |
| 05/03/2001 | CA2388077A1 Novel succinic acid metallo-beta-lactamase inhibitors and their use in treating bacterial infections |
| 05/03/2001 | CA2387921A1 Invasive bacterial vectors for expressing alphavirus replicons |
| 05/03/2001 | CA2387857A1 Tissue factor antagonists and methods of use thereof |
| 05/03/2001 | CA2387648A1 Oral formulations for anti-tumor compounds |
| 05/03/2001 | CA2387378A1 Processed human chemokines phc-1 and phc-2 |
| 05/03/2001 | CA2387098A1 6-methoxy-2-naphthylacetic acid prodrugs compositions for treating inflammation |
| 05/03/2001 | CA2386908A1 Treating sleep disorders using desloratadine |
| 05/03/2001 | CA2386889A1 Methods of treating hair loss comprising administering indoline compound |
| 05/03/2001 | CA2386750A1 Pharmaceuticals for treating obesity |
| 05/03/2001 | CA2386441A1 Method to treat pain utilizing benzimidazole nmda/nr2b antagonists |
| 05/03/2001 | CA2385929A1 Use of gdnf for treating corneal defects |
| 05/03/2001 | CA2385178A1 Naphthyridine derivative |
| 05/02/2001 | EP1096022A1 Immuno-stimulating polysaccharide substance from Phellinus spp. strain and use thereof |
| 05/02/2001 | EP1096021A2 Melanins with improved ability to inhibit HIV replication |
| 05/02/2001 | EP1095947A1 Novel antibacterial compounds |
| 05/02/2001 | EP1095941A1 Process and crystal forms of 2-methyl-thieno-benzodiazepine |
| 05/02/2001 | EP1095940A2 Derivatives of 9-(3,5-dimethoxyphenyl)-5,8,8a,9-tetrahydrofuro[3',4':6,7]naphto[2,3-d][1,3]dioxol-6(5aH)-one, method for their preparation and pharmaceutical compositions containing them |
| 05/02/2001 | EP1095939A2 Process for the preparation of piperidinylaminomethyl trifluoromethyl cyclic ether compounds |
| 05/02/2001 | EP1095936A1 Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation |
| 05/02/2001 | EP1095933A1 Novel N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them |
| 05/02/2001 | EP1095661A1 Prevention and treatment of biomaterial-associated infections |
| 05/02/2001 | EP1095660A2 Therapeutic combination containing terpinen-4-ol and medicinal plants |
| 05/02/2001 | EP1095658A2 Use of ribose to treat fibromyalgia |
| 05/02/2001 | EP1095657A2 Compositions for the regulation of cytokine activity |
| 05/02/2001 | EP1095656A2 Pharmaceutical preparation comprising Galanthamine as cholinesterase inhibitor |
| 05/02/2001 | EP1095655A2 NK-1 receptor antagonists and eletriptan for the treatment of migraine |
| 05/02/2001 | EP1095654A2 Use of raloxifene and its analogs for the manufacture of a medicament for the Inhibition of LDL oxidation and atherosclerosis |
| 05/02/2001 | EP1095652A2 Melanins with improved ability to inhibit HIV replication |
| 05/02/2001 | EP1095651A2 Multipor food protection |
| 05/02/2001 | EP1095279A1 Method for identifying a presenilinase inhibitor |
| 05/02/2001 | EP1095148A2 Cloning and characterisation of novel mammalian peptidases |
| 05/02/2001 | EP1095136A1 Cells and animals deficient in protein kinase c epsilon |
| 05/02/2001 | EP1095064A1 Amides of hyaluronic acid and the derivatives thereof and a process for their preparation |
| 05/02/2001 | EP1095050A1 Phosphorous organic compounds and their use |
| 05/02/2001 | EP1095044A1 Piperazynil pyrimidine dione compounds selective for adrenoceptors |
| 05/02/2001 | EP1095043A1 Trioxane derivatives |
| 05/02/2001 | EP1095042A1 Antiparasitic artemisinin derivatives (endoperoxides) |
| 05/02/2001 | EP1095040A1 New benzoxazoles with pde-inhibiting activity |
| 05/02/2001 | EP1095039A2 New pharmaceutically active compounds |
| 05/02/2001 | EP1095038A1 Antagonists of gonadotropin releasing hormone |
| 05/02/2001 | EP1095037A1 Improved process of synthesis of 5-methoxy- 2- (4-methoxy- 3,5-dimethyl- 2-pyridyl)methyl]sulfinyl-1h-benzimidazole |
| 05/02/2001 | EP1095036A1 Cinnamic acid derivatives as cell adhesion molecules |
| 05/02/2001 | EP1095031A1 Antiviral macrocyclic compounds |
| 05/02/2001 | EP1095029A1 Piperazine derivatives inhibiting human immunodeficiency virus replication |
| 05/02/2001 | EP1095026A1 Pharmaceutical agents |
| 05/02/2001 | EP1095025A2 Benzimidazoles, production thereof and use thereof as medicaments |
| 05/02/2001 | EP1095021A1 Quinoline derivatives |
| 05/02/2001 | EP1095020A1 2-aminopyridine erivatives, their use as medicines and pharmaceutical compositions containing them |
| 05/02/2001 | EP1095018A1 Aminoiminoquinone and aminoquinone alkaloid compounds as caspase inhibitors |
| 05/02/2001 | EP1095017A1 24,24-difluorinated analogs of 1-alpha,25-dihydroxy vitamin d3 |
| 05/02/2001 | EP1095016A1 Sulfur substituted sulfonylaminocarboxylic acid n-arylamides, their preparation, their use and pharmaceutical preparations comprising them |
| 05/02/2001 | EP1095015A2 Sulfonylamino carboxylic acid n-arylamides as guanylate cyclase activators |
| 05/02/2001 | EP1095007A1 Water-soluble zinc pyruvates or their hydrates, method for the production thereof and their use |
| 05/02/2001 | EP1095003A1 Cytokine production and tyrosine kinase inhibitors |
| 05/02/2001 | EP1095002A1 Method of vitamin production |
| 05/02/2001 | EP1094849A1 Methods for increasing vascularization and promoting wound healing |
| 05/02/2001 | EP1094843A1 Targeted site specific drug delivery compositions and method of use |
| 05/02/2001 | EP1094841A1 Pharmaceutical levothyroxine preparation |
| 05/02/2001 | EP1094840A1 Use of texaphyrins in macrophage-mediated disease |
| 05/02/2001 | EP1094826A1 Novel therapeutic agents that modulate alpha-1a adrenergic receptors |
| 05/02/2001 | EP1094823A2 Use of alpha-d-glucans for promoting cutaneous wound and ulcer healing |
| 05/02/2001 | EP1094822A1 Water miscible macrolide solutions |
| 05/02/2001 | EP1094820A2 Use of bisphosphonates in the treatment of vascular restenosis |
| 05/02/2001 | EP1094818A1 Use of tricyclic antidepressants for local analgesia |
| 05/02/2001 | EP1094817A1 Compositions comprising gaba analogs and caffeine |
| 05/02/2001 | EP1094816A1 Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
| 05/02/2001 | EP1094815A1 Farnesyl protein transferase inhibitors for treating arthropathies |
| 05/02/2001 | EP1094814A2 Methods and compositions for increasing penetration of hiv protease inhibitors |
| 05/02/2001 | EP1094813A2 Use of piperine for treating skin pigmentation disorders |
| 05/02/2001 | EP1094812A1 Angiogenesis inhibitors |
| 05/02/2001 | EP1094811A1 New use |
| 05/02/2001 | EP1094810A1 Use of prenyltransferase inhibitors for preparing a medicine for treating pathologies resulting from heterotrimeric g protein membrane fixation |
| 05/02/2001 | EP1094809A2 Use of histamine h2 mimicking substances for the treatment of multiple sclerosis |
| 05/02/2001 | EP1094808A1 Therapeutic combinations comprising a selective estrogen receptor modulator and parathyroid hormone |
| 05/02/2001 | EP1094807A1 Vitamin e and esters thereof for use in the topical treatment of mucosal pathologies |
| 05/02/2001 | EP1094806A2 Vasculoprotector |
| 05/02/2001 | EP1094805A1 Substituted oxygen alicyclic compounds, including methods for synthesis thereof |
| 05/02/2001 | EP1094804A2 The treatment of renal colic with gaba analogs |
| 05/02/2001 | EP1094803A2 Use of gaba-analogues for treating insomia |
| 05/02/2001 | EP1094802A1 Pharmaceutical composition for injection based on paracetamol |
| 05/02/2001 | EP1094801A2 Poly(diallylamine)-based bile acid sequestrants |
| 05/02/2001 | EP1094800A2 PEPTIDYL-PROLYL $i(CIS)-TRANS ISOMERASE INHIBITORS AND USES THEREFOR |
| 05/02/2001 | EP1094799A1 Apomorphine-containing dosage forms for ameliorating male erectile dysfunction |
| 05/02/2001 | EP1094798A2 INHIBITORS OF TYPE 5 AND TYPE 3 17beta-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE |
| 05/02/2001 | EP1094797A1 Transdermal plaster containing at least one active ingredient which influences blood serum lipid levels |
| 05/02/2001 | EP1094796A1 Topical plaster with non-steroidal antirheumatic agents with an acid group |
| 05/02/2001 | EP1094795A1 Therapeutic system with addition of nacreous pigments |
| 05/02/2001 | EP1094793A1 Composition containing glycerol trinitrate, method for producing said composition and use of the same |
| 05/02/2001 | EP1094791A1 Thixotropic formulations for filling capsules |